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Immuno-positron emission tomography (immuno-PET) is a noninvasive imaging method
that enables tracking of immune cells in living animals. We used a nanobody that
recognizes mouse CD8a and labeled it with 89Zr to image mouse CD8+ T cells in the
course of an infection with inﬂuenza A virus (IAV). The CD8+ signal showed a strong
increase in the mediastinal lymph node (MLN) and thymus as early as 4 days postinfection (dpi), and as early as 6 dpi in the lungs. Over the course of the infection, CD8+ T
cells were at ﬁrst distributed diffusely throughout the lungs and then accumulated more
selectively in speciﬁc regions of the lungs. These distributions correlated with morbidity as
mice reached the peak of weight loss over this interval. CD8+ T cells obtained from control
or IAV-infected mice showed a difference in their distribution and migration when
comparing their fate upon labeling ex vivo with 89Zr-labeled anti-CD8a nanobody and
transfer into infected versus control animals. CD8+ T cells from infected mice, upon
transfer, appear to be trained to persist in the lungs, even of uninfected mice. ImmunoPET imaging thus allows noninvasive, dynamic monitoring of the immune response to
infectious agents in living animals.
Keywords: immuno-PET, inﬂuenza A virus, CD8, T cells, imaging

INTRODUCTION
Inﬂuenza remains a serious disease, with an estimated 1 billion infections per year, some 290,000–
650,000 of which are fatal (1). Inﬂuenza A virus (IAV), a segmented, negative-sense RNA virus in
the family Orthomyxoviridae, causes seasonal epidemics. IAV can also cause pandemics, during
which individuals have limited cross-protective immunity as a result of the virus’s ability to reassort
its segments with heterologous inﬂuenza strains (2, 3). Despite the development of antivirals and
vaccines, inﬂuenza virus-associated deaths remain a major concern. A better understanding of the
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clinical course of infection and the host’s immunological
response to the virus is crucial to improve vaccines and
therapeutics against inﬂuenza viruses.
IAV, along with the related inﬂuenza B virus, causes a range
of clinical manifestations, from mild self-limiting respiratory
tract infections, to progressive and sometimes lethal pneumonia
(4). Both the upper and lower respiratory tracts are sites of viral
replication, with nascent virions spreading amongst epithelial
cells of the upper respiratory tract and trachea in most non-fatal
cases. Lower respiratory involvement and pneumonia, caused by
the virus and/or secondary bacterial infections, are often seen in
fatal cases (5).
Upon detecting the presence of IAV infection, the host
immune system clears the viral infection using both innate and
adaptive immune components (6). The rapid induction of innate
defenses is critical for early protection and limits viral spread to
host tissues, while adaptive immunity develops. Early stages of
innate immunity include the rapid production of type I
interferons (IFNs), cytokines, and chemokines through
activation of pattern recognition receptors, which in turn
attracts inﬂammatory cells to the airways to help clear the
infection and prepare the host for the adaptive immune
response (7). The adaptive immune response is activated when
lung-resident dendritic cells sense cytokines and acquire debris
from infected, dying cells, which induces their migration from
the inﬂamed lungs to the lung-draining lymph nodes (DLNs).
There, they display newly acquired viral antigen(s), processed to
yield peptide-MHC complexes (8). Naïve T cells in the DLNs
recognize these complexes, expand clonally, and then
differentiate into IAV antigen-speciﬁc CD8+ and CD4+ effector
T cells (9). Secondary lymphoid organs, such as DLNs and the
spleen, provide the spatial organization and appropriate
chemokine environment to prime the antiviral immune
response by bringing together Th1 CD4+ and naïve CD8+ cells
to generate inﬂuenza-speciﬁc CD8+ cytotoxic T lymphocytes
(CTLs). Virus-speciﬁc T lymphocytes then migrate to the site of
infection in response to cytokines and chemokines, and B cells
are primed to secrete neutralizing antibodies (10).
The virus itself causes extensive damage to and desquamation
of the airway epithelium, but effector T cells also contribute to
tissue damage directly by secreting granzymes and perforin, as
well as by inducing FasL- and TRAIL-mediated apoptotic
pathways (5, 11). CTL-induced tissue damage, however, is
thought to be more extensive as a consequence of indirect
mechanisms, such as by secretion of pro-inﬂammatory
molecules that recruit other players to the site of infection,
including IFNg, macrophage inﬂammatory protein-1a, and
CTL-derived tumor necrosis factor-a (12–18). Observing the
spatiotemporal behavior of CTLs during IAV infection, ideally
longitudinally and noninvasively, is essential to better
understand the immunopathology induced by these cells and
to eventually prevent collateral damage inﬂicted by T cells.
One technique used to visualize and track cells in vivo is
positron emission tomography (PET), which is used to identify
tumors in humans. PET scanning relies on detection of a
radiotracer, such as 18 F-2-ﬂuorodeoxyglucose, which is
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absorbed by tumor cells with high metabolic activity. ImmunoPET is a technique that uses radiolabeled antibodies, or antibody
fragments, that target disease- or cell-speciﬁc antigens to track
the distribution of that antigen (19, 20). We have used immunoPET, more speciﬁcally using single domain antibody fragments
(VHHs or nanobodies) derived from alpaca heavy chain-only
antibodies, to track immune cell distribution and inﬁltration in
graft-versus-host disease, as well as in models of cancer and the
immune response to cancer therapies (21–23).
We used radiolabeled nanobodies to study the kinetics of
CD8+ T cell recruitment to the site of infection, using mouseadapted IAV. We also identiﬁed the localization of CD8+ T cells
from IAV-infected and control mice upon transfer to assess cellautonomous migratory behaviors. By transferring labeled CD8+
T cells from IAV-infected mice into either healthy or IAVinfected recipients, we examined whether the inﬂamed
environment of the infected lungs affects tissue-speciﬁc
trafﬁcking of both naïve and antigen-speciﬁc T cells. Prior
studies have relied mostly on invasive techniques, such as
tissue harvest, followed by ﬂow cytometry to enumerate CD8+
T cells in the organ of interest. While this provides insight into
the local distribution of CD8+ T cells, it does not provide
information on changes in distribution or migration of CD8+
T cells to peripheral tissues in the course of infection. We show
that it is possible to noninvasively monitor the total population
of CD8+ T cells over the course of an IAV infection at millimeter
spatial resolution. This approach provides a new means to track a
CD8+ T cell response noninvasively in a living animal.

MATERIALS AND METHODS
Synthesis of Peptide Probes for
Sortase Reactions
Peptide GGGCGGSK(azide) with a free N-terminus and Cterminal amide was synthesized following standard solid phase
synthesis protocols (24). All Fmoc amino acids were purchased
from Chempep, Inc. Fmoc-Lys(azide)-OH was used as a building
block to provide the bioorthogonal handle. Peptides were
puriﬁed by reverse phase HPLC. Their identity was conﬁrmed
by LC-MS prior to maleimido-DFO coupling to the cysteine
thiol. Peptides were further puriﬁed by reverse phase HPLC and
their identity was conﬁrmed again by LC-MS.

C-Terminal Sortagging and PEGylation
Ca2+-independent heptamutant sortase A derived from S. aureus
(10 mM ﬁnal concentration, 10x stock in 50 mM Tris, pH 7.4, 150
mM NaCl) and probe (1 mM ﬁnal concentration, 50x stock)
were added to VHH-X118 (200 mM ﬁnal concentration) in
phosphate-buffered saline (PBS). The resulting mixture was
incubated at 4°C overnight. Ni-NTA (0.5 ml) was added to the
reaction mixture and incubated for 20 minutes to remove sortase
and unreacted VHHs. The mixture was centrifuged and the
supernatant was collected and puriﬁed by size exclusion
chromatography (Superdex 75- GE Life Sciences), and
analyzed by SDS-PAGE and LC-MS. PEGylated VHH-X118
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was generated by reacting the bioorthogonal azide group with
dibenzocyclooctyne DBCO-(PEG)20 overnight. The end product
was analyzed by SDS-PAGE to conﬁrm efﬁcient coupling.

lungs, and preset CT intensities (-1400, 400) were used to generate
the lung ROIs. For the MLN region, ROIs were generated by
creating a spherical region with a 10-pixel diameter centered
around the point of highest PET intensity of MLN. An additional
ROI was drawn in the quadriceps muscle of the hind leg of each
mouse, avoiding bones and LNs, which was subtracted as
background. Once all ROIs were generated, statistical information
for each ROI containing mean PET signal, was exported and
processed. We normalized signal intensities to background signal
for each mouse by using the ratio between PET signal in the lungs or
MLN to PET signal in the quadriceps muscle. The level of
signiﬁcance was determined using a Student’s t-test.

Virus Quantiﬁcation
IAV was quantiﬁed by ﬂow cytometry, using a method adapted
from one previously described (25). Brieﬂy, conﬂuent MadinDarby canine kidney cells were infected in triplicate with 2-fold
serial dilutions of IAV WSN/33 (in DMEM, 0.2% BSA) for 1
hour. The inoculum was removed and replaced with DMEM,
0.2% (w/v) BSA for 5 hours. Cells were washed with PBS,
trypsinized, and ﬁxed with 4% formaldehyde in PBS. Cells
were stained with 1 mg/ml VHH62 (anti-IAV NP)-Alexa Fluor
647 under permeabilizing conditions. Fluorescence was
quantiﬁed using a BD Accuri C6 Plus. The NP-positive
population was determined by comparison with an uninfected
control population (Figure S1A). Data were processed using the
FlowJo software package (TreeStar Inc). A linear regression
model was applied (Figure S1B). The slope of the line of best
ﬁt was used to determine the percentage of infected cells, which
was multiplied by the number of cells per well to yield the
number of viral particles per well.

T Cell Puriﬁcation
Mice were euthanized by asphyxiation with CO2 and spleens
were extracted by dissection. Spleens were homogenized into
single-cell suspensions. Red blood cells were removed by
hypotonic lysis. T cells were isolated from these splenocytes
using the Dynabeads® Untouched™ Mouse T Cells Kit following
the suppliers’ recommended procedures. The lungs of day 9infected CD45.2 C57BL/6J mice were extracted by dissection,
and T cells were isolated using the Dynabeads® Untouched™
Mouse T Cells Kit with additional incubations with anti-CD326
and anti-CD31 antibodies to deplete epithelial and endothelial
cells, respectively.

Infection of Mice With IAV
Age-matched, 6-week old, female CD45.2 C57BL/6J mice (n≥3
in each group) were purchased from the Jackson Laboratory.
Mice were anesthetized with isoﬂurane and infected by the
intranasal route with 4 x 104 infectious units of IAV WSN/33
diluted in PBS. Control mice were similarly given an equal
volume of PBS intranasally. Infection was tracked by
monitoring daily weight loss. Mice were euthanized with CO2
when weight loss exceeded 25% of initial body weight and/or
animals displayed signs of severe distress, or if no weight was
recovered 9 dpi.

Flow Cytometry
Aside from virus quantiﬁcation assays, all data were acquired on
a Fortessa instrument (BD Biosciences) and analyzed using
FlowJo software Cells obtained from the lungs and MLN of
CD45.2 C57BL/6J mice were used for ﬂow cytometry. Cells were
resuspended in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4) with 2% (v/v) fetal bovine serum
and passed through 40-mm cell strainers to obtain single-cell
suspensions prior to antibody staining (30 minutes at 4°C). All
antibodies were obtained from BioLegend (San Diego, CA).
Student’s t-test was applied for statistical analysis.

Immuno-PET Imaging
IAV-infected and control mice were anesthetized using
isoﬂurane and injected via the retro-orbital route with
approximately 25 mCi of 89Zr-VHH-X118-PEG20. PET-CT
procedures have been described in detail (21, 26). Brieﬂy,
approximately 24 h post-administration of 89Zr-VHH-X118PEG20, mice were anesthetized using 2% isoﬂurane in O2 at a
ﬂow rate of approximately 1 L/minute. Mice were imaged with a
G8 PET-CT small-animal scanner (PerkinElmer). PET images
were acquired over a 20 minute period, which was followed by
approximately 2 minutes of CT acquisition. As a standard for
absolute intensity, a ﬁxed quantity of radioactivity was imaged
using 5-fold serial dilutions of radioisotope in PCR strip tubes.

ELISpot Assay
96-well ELISpot plates (BD ELISPOT Mouse IFNg ELISPOT Set,
BD Biosciences, San Jose, CA) were coated with an IFNg capture
antibody (BD Biosciences) in PBS overnight at 4°C, followed
by incubation with complete RPMI-1640 medium for 2 hours
at room temperature (RT). Single cell suspensions from
selected organs of IAV-infected and uninfected mice were
prepared. Red blood cells were removed by hypotonic lysis.
Quadruplicate ELISpot wells containing mononuclear cells,
were supplemented with the IAV NP peptide (366-374;
ASNENMETM) (2 mg/ml), to serve as a H2-Db-restricted
epitope from the Inﬂuenza A/PR/8/34 nucleoprotein (27, 28).
As a control, medium without added IAV peptide was used.
ELISpot plates were incubated at 37°C for 18 hours, washed and
incubated with a biotinylated IFNg detection antibody (BD
Biosciences) for 2 hours, followed by incubation with a
streptavidin-horse radish peroxidase (HRP) conjugate (BD
Biosciences) for 1 hour at RT. ELISpot plates were developed
with 3-amino-9-ethyl-carbazole substrate (BD ELISPOT AEC

PET Quantiﬁcation
We processed and quantiﬁed PET images using VivoQuant
software. The CT scan was used as a guide to generate 3D
regions of interest (ROIs) to represent regions corresponding to
the lungs and MLN. ROIs were drawn for each image
corresponding to the absence of CT signal in the ribcage,
surrounding the heart as a means of identifying pulmonary space.
We used preset CT values to view the area corresponding to the
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Substrate Set) and dried. Spots were counted using an
ImmunoSpot Analyzer.

lysine in the course of synthesis of the nucleophile to incorporate
polyethylene glycol (PEG) moieties for in vivo injections,
effectively reducing non-speciﬁc retention in the kidneys
(Figure 1) (21). The agent used for ex vivo labeling of CD8+ T
cells prior to use in transfer experiments, as described below, did
not include a PEG moiety.

Ex Vivo T Cell Activation
Splenocytes from CD45.2 C57BL/6J mice were cultured in plates
pre-coated with anti-CD3 (5 µg/ml) and anti-CD28 (1 µg/ml)
antibodies in complete RPMI-1640 medium supplemented with
250 ng/ml of mouse IL-2 produced in house. Following
activation for 24 hours, cells were transferred to fresh dishes
without anti-CD3 and anti-CD28 in complete RPMI-1640
supplemented with 250 ng/ml of mouse IL-2, followed by
two additional days of culture. Cells were washed three
times with PBS and cell numbers were determined prior to
transfer experiments.

CD8+ T Cells Transiently Accumulate
in the Lungs and Mediastinal Lymph
Nodes (MLN) of IAV-Infected Mice,
Correlating With Morbidity
To establish the whole-body distribution of CD8+ T cells during
IAV infection, we acquired CD8+ PET images using 89Zr-labeled
VHH-X118, and in parallel, tracked weight loss after intranasal
inoculation of CD45.2 C57BL/6J mice (n≥3 for each group) with
a sub-lethal dose (4 x 104 infectious units) of inﬂuenza A/WSN/
33 virus (H1N1). In uninfected mice, CD8+ T cells were
distributed in the cervical, axillary and brachial (lung
draining), mediastinal (lung draining), popliteal, renal, iliac,
and inguinal lymph nodes, as well as in the spleen, consistent
with previous observations (21). PET signals in the organs of
elimination (kidneys, liver and bladder) and the site of injection
(retro-orbital plexus) are non-speciﬁc and common occurrences
when using nanobodies as imaging agents (21, 30, 31). During
the ﬁrst week of IAV infection, mice experienced weight loss,
paralleled by increases in PET signal in the mediastinal lymph
node (MLN) and lungs (Figure 2). Attribution of PET signals to
particular anatomical structures was conﬁrmed by imaging
dissected organs, including MLN, lungs, heart, and thymus
(Figure S2). At 4 days post-infection (dpi), mice showed a
striking increase in CD8+ T cells in the area corresponding to
the MLN and in the draining lymph nodes, as inferred from the
PET signal. At the peak of infection (6 dpi) as determined by
weight loss, a diffuse pattern of CD8 signal was present in the
lungs, likely caused by CD8+ T cell migration from secondary
lymphoid organs towards particular foci of infection. This signal
became more concentrated and localized in speciﬁc regions of
the lungs over the course of the infection, starting at 9 dpi. The
PET signal decreased around 18 dpi, when mice regained weight
in the recovery phase, and ﬁnally disappeared from the lungs by
21 dpi.

T Cell Transfer
Cells were labeled with non-PEGylated 89Zr-VHH-X118 in PBS
at 4°C for 20 minutes with constant agitation. Cells were then
washed three times with PBS to remove unbound 89Zr-VHHX118. Labeled cells (6 x 106) were then transferred into the retroorbital plexus of each CD45.1 C57BL/6J mouse. Images were
acquired as previously described 1 and 24 h post-T cell transfer.

FACS
T cells puriﬁed from lungs of day 9-infected CD45.2 BL/6J mice
were stained with FITC anti-mouse CD8 and Alexa700 antimouse CD45.2 antibodies (BioLegend). The CD8+CD45.2+ T cell
population was sorted on a BD FACSAria III sorter.

Ethics Statement
All animal protocols were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. All animals were maintained
according to the guidelines of the Animal Resources Children’s
Hospital. These studies were approved by the Boston Children’s
Hospital Institutional Animal Care and Use Committee
(protocol #16-12-3328). All infections and PET imaging
procedures were performed under isoﬂurane anesthesia and all
efforts were made to minimize suffering.

RESULTS
VHH Construct Design for Immuno-PET
Imaging of CD8+ T Cells

Immuno-PET Shows Accumulation
of CD8+ T Cells in the Lungs and
MLN of IAV-Infected Mice

In order to follow CD8+ T cells noninvasively over the course of
IAV infection, we used a VHH speciﬁc for murine CD8a, VHHX118 (21). We produced two versions of 89Zr-labeled VHHX118, both made via modiﬁcation of the VHH’s C-terminal
sortase recognition motif (LPETG). This modiﬁcation allows the
use of a peptide containing an N-terminal GGGC sequence
equipped with a radiometal chelator to serve as a nucleophile
in a sortase A-mediated transpeptidation reaction (29). By
incorporation of maleimido-desferrioxamine (DFO), we
installed 89Zr for PET imaging. We also generated a PEGylated
version of 89Zr-labeled VHH-X118 by using an azide-substituted

In order to determine whether the PET signals observed in the
lungs and MLN of mice over the course of infection constituted
measurable signiﬁcant increases, we quantiﬁed the PET signal
from the animals in Figure 2 using VivoQuant software.
Speciﬁcally, we generated 3D regions of interest (ROIs)
representing the lungs (Figure 3A; cyan), MLN (Figure 3B;
cyan), and quadriceps muscle (control; green) to quantify the
PET signal within the volume of the ROI. Mean intensity was
calculated by dividing the PET signal by the volume of the ROI.
This value was further normalized within each mouse to the
intensity of the quadriceps muscle, in order to account for possible
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FIGURE 1 | VHH Construct and Design. Schematic of the VHH-X118 construct used to track CD8+ T cells in vivo. A representative VHH structure (PDB: 3OGO) is
shown covalently bound to the peptide probe LPETGGCGGS. Maleimido-DFO (grey), which was covalently linked to the peptide probe at the cysteine thiol, is shown
chelating 89Zr (red). A terminal, azide-substituted lysine was covalently modiﬁed with a PEG20 substrate (peach) for improved circulation.

population (Figure 4A). The number of inﬁltrating lymphocytes
in the lungs of day 9-infected mice was signiﬁcantly increased
(Figure 4C), in agreement with the observed increase in PET
signal. To better identify the T cell subset present in the inﬁltrating
population and to establish the percentage of CD44+CD62L+
[central memory T cells (TCM)] and CD44+CD62L- [effector T
cells (TEFF/TEM)] cells, we gated on either the CD8+ or CD4+ T cell
population (Figure 4B). The majority of inﬁltrating CD8+ and
CD4+ T cells in the lungs were CD44+CD62L- (TEFF/TEM). No
signiﬁcant increase in CD8+CD44+CD62L+(TCM) was detected in
the lungs of the infected animals (Figure 4C).

variations in multiple experiments and across mice. CD8 signal
intensity in the lungs increased during infection and remained
elevated from days 6 through 12 of IAV infection. Lung signal
decreased after day 12, as mice recovered from IAV infection.
These results correlate with morbidity, as mice reached the peak of
their weight loss in this interval (Figure 2, inset graphs). Similarly,
we observed a trend towards an increase in CD8 signal intensity in
the MLN beginning at 4 dpi, which reached signiﬁcance (P<0.05)
between days 9 and 15 of the infection, before eventually
decreasing during the recovery phase of the infection
(Figures 3C, D). An increase in CD8 signal intensity should be
detectable in the MLN of infected mice prior to its appearance in
the lungs, as T cells are activated in lymph nodes prior to
migrating to the lungs in response to chemokines (32).

The Lung-Inﬁltrating Population Contains
IAV-Speciﬁc T Cells
We next conﬁrmed that IAV-speciﬁc T cell responses could be
detected in the lungs, MLN, and spleen by using a peptide
corresponding to the immunodominant H-2Db-restricted IAV
NP epitope, ASNENMETM, in an IFNg ELISpot assay. As
expected, we saw an increase in the number of IAV-speciﬁc
CD8+ T cells in the lungs, MLN, and spleen in infected mice
(Figure 4D). We detected low levels of IFNg-producing cells in

T Cells in Day 9-Infected Lungs Are
Predominantly CD8+ TEFF/TEM Cells
To characterize the population of inﬁltrating T cells at 9 dpi and
uninfected mice, we performed ﬂow cytometry on cells isolated
from the lungs and MLN. The ratio of inﬁltrating CD4+ versus
CD8+ T cells was determined by gating on the CD3+CD45+
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FIGURE 2 | CD8+ T Cells Transiently Accumulate in the Lungs and MLN of IAV-Infected Mice, Correlating with Morbidity. Representative (n ≥ 3) immuno-PET
images of IAV WSN/33-infected mice (facing down) injected with 89Zr-labeled VHH-X118-PEG20 on the indicated dpi. Graphs below immuno-PET images show
percent initial weight for each day over the course of IAV infection for the cohort of animals. Insets to the right depict focused images of the MLN and lungs at
the times indicated. Lower case letters link inset images to their corresponding full-body image, and single and double apostrophes indicate MLN and lung
insets, respectively.

the media-only controls in the lungs from infected animals,
presumably due to the persistence of antigen and/or previously
activated IFNg-producing T cells.

insult display lung homing properties, independent of whether
the lungs are infected or not? In any case, little is known about
the in vivo distribution of T cells immediately after transfer into
recipients. We approached these questions by transfer of 89Zr
anti-CD8a-labeled CD8+ T cells to trace their distribution in the
recipients at 1 hour and 24 hours post-transfer, using wholebody immuno-PET imaging. T cells were harvested and puriﬁed
from the lungs of IAV-infected mice 9 dpi, with additional
negative selection steps to remove epithelial and endothelial
cells, followed by cytoﬂuorimetry to assess purity of the T cell
population to be transferred. We likewise harvested splenocytes
from uninfected control mice and puriﬁed CD8+ T cells from
them. These naïve T cells were then activated on plate-bound

Distribution of Transferred CD8+
T Cells Relies on the Mechanism
of T Cell Activation and the Local
Inﬂammatory Environment
Transfer of virus-speciﬁc CD8+ T cells can clear IAV in a B celldeﬁcient mouse model (33). In such settings, the tissue
distribution of donor CD8+ T cells remains unclear. Does the
inﬂamed environment of the lungs provide signals that direct
and retain T cells? Do T cells instructed to deal with a pulmonary
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A

B

C

D

FIGURE 3 | Quantiﬁcation of CD8+ T Cell Immuno-PET Signal in the Lungs and MLN/Thymus. (A, B) The volume of the lungs (cyan) was determined using the
VivoQuant 3D ROI tool in each mouse based on CT signal (white/grey) (A). The volume of the MLN (cyan) was deﬁned based on PET intensity (B). In each mouse,
PET intensity was normalized to background signal as deﬁned by a ROI in the quadriceps muscle (green). Mice are shown facing down as 3D renderings (left) and in
slices: frontal (top right), sagittal (middle right), and transverse (bottom right) ROI. (C, D) PET intensity from the lung ROI (C) for each day was normalized to the PET
intensity of day 0, uninfected mice (n = 3). Student’s t-tests were used to compare infected mice at each time point to uninfected mice. *P < 0.05.

remained there after 24 hours. CD8+ T cells from day 9-infected
mice initially migrated to the lungs and spleen when transferred
into day 4-infected and uninfected recipients, imaged 1 hour
post-transfer (Figure 5B, bottom panels). After 24 hours, a signal
corresponding to these CD8+ T cells remained detectable in the
lungs of day 4-infected mice and appeared to increase in intensity
in the spleen and MLN. Uninfected mice also retained a signal
corresponding to CD8+ T cells from infected mice in their lungs
24 hours post-transfer, but to a lesser extent, probably due to the
lack of an inﬂammatory environment. CD8+ T cells harvested
from day 9-infected mice did not initially populate the spleens of
uninfected mice in large numbers, nor did they appear to migrate
there over the 24 hour observation period.

anti-CD3 and anti-CD28, in medium supplemented with IL-2
(34). CD8+ T cells from day 9-infected mice or activated CD8+ T
cells from control mice were labeled in suspension with 89ZrVHH-X118. Labeled cells were then transferred into either IAVinfected (4 dpi) or uninfected control mice via retro-orbital
injection. PET images were acquired at 1 hour and 24 hours
post-transfer (Figure 5A).
Upon transfer into day 4-infected recipient mice, ex vivo
activated, control CD8+ T cells initially localized to the lungs and
spleen (Figure 5B, top panels). After 24 hours, the signal
corresponding to CD8 + T cells decreased in the lungs.
Activated CD8+ T cells generated from control splenocytes
transferred into naïve mice localized mostly to the spleen and
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A

B

C

D

FIGURE 4 | Lung-Inﬁltrating Cells are Predominantly CD8+ TEFF/TEM Cells, a Signiﬁcant Amount of Which are IAV Speciﬁc. (A) The inﬁltrating T cells were gated on
CD45+CD3+ and the ratio of CD4+ and CD8+ was determined. (B) CD8+ and CD4+ TEFF/TEM (CD44hiCD62Llo) and TCM (CD44hiCD62Lhi) were gated on
CD45+CD3+CD4+CD44+CD62L- and CD45+CD3+CD8+CD44+CD62L+. (C) Statistical analysis of data from (A, B). (D) IAV-speciﬁc T cell responses in lungs, MLN,
and spleen as determined by an ELISpot assay. Representative ELISpot wells are shown in the left panel and statistical analyses of lungs, MLN, and spleen IAVspeciﬁc T cells are shown in the right panel.
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A

B

FIGURE 5 | Distribution of Transferred CD8+ T Cells Relies on the Site of T Cell Maturation and Local Inﬂammatory Environment. (A) Schematic depicting CD8+ T
cell transfer experiments. Donor mice were infected with IAV WSN/33 and CD8+ T cells were harvested from the lungs at 9 dpi. Harvested CD8+ T cells were ex vivo
labeled with 89Zr-VHH-X118 and injected into day 4-infected or uninfected mice. As a control, CD8+ T cells were puriﬁed from naïve splenocytes of uninfected mice,
ex vivo activated, and injected into day 4-infected and uninfected mice. Mice were immuno-PET imaged 1 hour and 24 hours post-transfer. (B) Day 4-infected or
uninfected recipient mice, shown face down, were immuno-PET imaged at the indicated times post-transfer of 89Zr-labeled T cells from the indicated donor source.
A standard with set amounts of radioactivity in 2-fold dilutions starting at 0.4 mCi is on the lower right side of each image. Data are representative of 2 experiments.

MLN, where CD8+ T cells are activated by antigen presenting
cells that present IAV-speciﬁc antigens (35). CD8+ T cells then
migrate to the lungs in response to chemotactic cues, where they
can be detected diffusely, but in signiﬁcant numbers at 6 dpi,
when mice experience peak weight loss. At 9 dpi, CD8+ T cells

DISCUSSION
We determined the whole-body distribution of CD8+ T cells in a
living mouse in the course of infection with IAV. An increase in
CD8+ T cells was ﬁrst detectable in lymph nodes, speciﬁcally the
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showed more discrete sites of accumulation in the infected lungs.
They remained there in elevated numbers until 12 dpi. CD8+ T
cells then left the lungs as mice recovered. The CD8+ T cell signal
remained elevated in the MLN throughout the infection,
followed by a gradual decrease in signal strength as the
infection waned.
Following viral infection, most pathogen-speciﬁc T cells
undergo a process of contraction by apoptosis. A small fraction
of the remaining antigen-speciﬁc T cells differentiate into memory
cells (9). Effector memory T cells (CD8+ CD44 + CD62L - )
recirculate in the blood and non-lymphoid tissues. They protect
the host against re-infection by their ability to kill cells infected
with inﬂuenza virus and by the production of inﬂammatory
cytokines at the site of infection (36). Central memory T cells
(CD8+CD44+CD62L+) take up residence in secondary lymphoid
organs. They proliferate, differentiate, and migrate to new sites of
infection (9). At 9 dpi with IAV, most CD8+ T cells in the lungs are
effector memory T cells.
As summarized in Figure 6, CD8+ T cells obtained from IAVinfected mice (9 dpi), upon transfer, initially populate the lungs of
both infected and uninfected mice. A CD8 signal remains
detectable there after 24 hours. Lymphocyte function-associated
antigen 1 (LFA-1) not only directs migration but also mediates
retention of effector CD8+ T cells in the lungs. LFA-1 interacts
with intercellular adhesion molecules (ICAMs) on endothelial cells
to allow leukocyte migration across the endothelium to sites of
inﬂammation (37). Normal, healthy lung tissue supports retention
of activated CD8+ T cells. Indeed, ICAM-1, an LFA-1 ligand, is
expressed in healthy lung tissue (38). In contrast, T cells activated

ex vivo with anti-CD3 and anti-CD28 more transiently localized to
the lungs of IAV-infected recipients, and did not populate the
lungs of uninfected recipients in a manner that was detectable by
immuno-PET imaging. This suggests that the inﬂamed status of
the lungs provides signals, probably in the form of both soluble
mediators and surface molecules, that allow retention of activated
T cells, regardless of their speciﬁcity, whereas healthy lungs do not
provide such cues. Ex vivo activated CD8+ T cells initially
populated the lungs of IAV-infected mice, presumably due to
the pro-inﬂammatory signals resulting from infection. Signal is
still detectable in the lungs 24 hours post-transfer, albeit of lesser
intensity. We hypothesize that the absence of IAV antigens from
control mice and the corresponding lack of continued engagement
of the TCRs on transferred ex vivo activated T cells likely
contribute to this phenotype. Further, the gene expression
proﬁles of ex vivo activated and in vivo activated IAV-speciﬁc
CD8+ T cells likely differ, which may contribute to their ability to
interact with lung-expressed retention ligands. It is also possible
that IAV-speciﬁc CD8+ T cells die upon transfer to uninfected
recipients, which could explain why they appear to be retained in
the lungs; however, it is unclear why antigen-speciﬁc CD8+ T cells
would die, while activated, non-speciﬁc T cells would retain the
capacity to migrate post-transfer. These are subjects of
future investigation.
In this study we show that 89Zr-labeled single-domain antibody
fragments can track the CD8+ T cell response to IAV infection
noninvasively in a living mouse. Nanobodies have several
advantages for use in PET imaging when compared to intact Ig
or Fab fragments. The small size of a nanobody (~12–16 kDa)

FIGURE 6 | Model of CD8+ T Cell Transfer to Infected and Uninfected Mice. CD8+ T cells transferred from day 9-infected mice (green) initially localize to the lungs
and spleen of uninfected (left) and IAV-infected (right) mice. After 24 hours, these cells are retained in the lungs and spleen of both uninfected and infected mice,
though retention is not as strong in the lungs of uninfected mice. Additionally, a subset of these cells migrates to the MLN of infected mice after 24 hours.
Transferred ex vivo activated CD8+ T cells (yellow) initially localize to the spleen of both uninfected and infected mice, and in both cases remain there after 24 hours.
While these cells do not localize to the lungs of uninfected mice, they do transiently populate the lungs of infected mice; however, these cells are not retained in the
lungs after 24 hours.
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enables access to epitopes not available for binding to conventional
Ig, provides improved tissue penetration, high stability, and rapid
renal clearance from the body of unbound nanobodies (39–42).
Further, nanobodies can be produced in high yield and in active
form in bacteria (43). A possible drawback of nanobodies for in vivo
use is their immunogenicity; while nanobodies are typically poorly
immunogenic in vivo, this is not always the case. Even then,
immunogenicity can often be modulated by modiﬁcation of the
framework regions of the construct (39, 40, 44, 45).
The platform used in this study is highly amenable to
adaptation. Addition of a sortase recognition motif to the Cterminus of a nanobody enables rapid and efﬁcient covalent
modiﬁcation of the nanobody. We used sortase to append a
radiometal chelator to the nanobody of interest. Modiﬁcation of
this strategy is simple owing to the commercial availability of
many different chelators with various functionalized handles.
The sortase reaction also enabled us to append PEG20 to the
nanobody of interest to increase circulatory half-life and decrease
renal retention of the construct; PEGylation of a construct is not
always required, and the size of the PEG moiety can be adjusted
according to the needs of the experiment (43). The choice of
available PET isotopes and their characteristic half-lives (68Ga:
~60 min; 18F: ~110 min; 64Cu:~12 hrs; 89Zr: ~3.3 days) sets
differing observation windows, which can be matched to the
immunological parameters of interest by the choice of a VHH of
appropriate speciﬁcity.
We propose that immuno-PET can be used to study the
immune response to any infection that induces CD8+ T cells The
signature advantage of this method is its noninvasiveness. More
conventional methods require sacriﬁcing the animals to enable
organ retrieval by dissection. Additional VHHs can, of course, be
developed against antigens from other animal models and can be
used to track various immune cells. Because of this, we propose
that immuno-PET can be utilized to monitor immune responses
to vaccines and to garner a better understanding of their
mechanisms of action.
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